BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 30577210)

  • 1. New-Onset Diabetes After Transplantation: Comparison Between a Cyclosporine-Based and a Tacrolimus-Based Immunosuppressive Regimen.
    Zolota A; Miserlis G; Solonaki F; Tranda A; Antoniadis N; Imvrios G; Fouzas I
    Transplant Proc; 2018 Dec; 50(10):3386-3391. PubMed ID: 30577210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of type of calcineurin inhibitor on post-transplant tuberculosis: Single-center study from India.
    Agarwal SK; Bhowmik D; Mahajan S; Bagchi S
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27775825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion from tacrolimus to cyclosporine in patients with new-onset diabetes after renal transplant: an open-label randomized prospective pilot study.
    Rathi M; Rajkumar V; Rao N; Sharma A; Kumar S; Ramachandran R; Kumar V; Kohli HS; Gupta KL; Sakhuja V
    Transplant Proc; 2015 May; 47(4):1158-61. PubMed ID: 26036543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up after conversion from tacrolimus to cyclosporin in renal transplant patients with new-onset diabetes mellitus after transplantation.
    Batista F; Auyanet I; Torregrosa JV; Oppenheimer F
    Transplant Proc; 2012 Nov; 44(9):2582-4. PubMed ID: 23146461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Frequency of T-cell mediated rejection in new-onset diabetes after kidney transplantation].
    Borda B; Szederkényi E; Lengyel C; Várkonyi T; Hódi Z; Kemény É; Szabó V; Lázár G
    Orv Hetil; 2015 May; 156(19):785-9. PubMed ID: 26039918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of tacrolimus and the development of posttransplant diabetes mellitus: a Brazilian single-center, observational study.
    Gnatta D; Keitel E; Heineck I; Cardoso BD; Rodrigues AP; Michel K; Garcia VD
    Transplant Proc; 2010 Mar; 42(2):475-8. PubMed ID: 20304169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporine versus tacrolimus maintenance therapy in renal transplant.
    Alghamdi S; Nabi Z; Skolnik E; Alkorbi L; Albaqumi M
    Exp Clin Transplant; 2011 Jun; 9(3):170-4. PubMed ID: 21649564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Side effects of the calcineurin inhibitor, such as new-onset diabetes after kidney transplantation.
    Borda B; Lengyel C; Várkonyi T; Kemény E; Ottlakán A; Kubik A; Keresztes C; Lázár G
    Acta Physiol Hung; 2014 Sep; 101(3):388-94. PubMed ID: 25183511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation.
    Song JL; Gao W; Zhong Y; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Wu H; Xu MQ; Chen ZY; Wei YG; Jiang L; Yang J
    World J Gastroenterol; 2016 Feb; 22(6):2133-41. PubMed ID: 26877618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature.
    Ghisdal L; Bouchta NB; Broeders N; Crenier L; Hoang AD; Abramowicz D; Wissing KM
    Transpl Int; 2008 Feb; 21(2):146-51. PubMed ID: 17971033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infection rates in tacrolimus versus cyclosporine-treated pediatric kidney transplant recipients on a rapid discontinuation of prednisone protocol: 1-year analysis.
    Kizilbash SJ; Rheault MN; Bangdiwala A; Matas A; Chinnakotla S; Chavers BM
    Pediatr Transplant; 2017 Jun; 21(4):. PubMed ID: 28371243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Factors Affecting Graft and Patient Survivals After Transplantation From Deceased Donors in a Developing Country: A Single-Center Experience.
    Ayar Y; Ersoy A; Ocakoglu G; Yildiz A; Oruc A; Soyak H; Calapkulu M; Sahin AB; Topal NB; Okeer E; Coskun B; Kaygisiz O; Kordan Y; Vuruskan H
    Transplant Proc; 2017 Mar; 49(2):270-277. PubMed ID: 28219583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential cardiovascular risk factors in paediatric renal transplant recipients.
    Ferraris JR; Ghezzi L; Waisman G; Krmar RT
    Pediatr Nephrol; 2006 Jan; 21(1):119-25. PubMed ID: 16252106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
    Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
    Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up.
    Lee YJ; Kim B; Lee JE; Kim YG; Kim DJ; Kim SJ; Joh JW; Oh HY; Huh W
    Transpl Int; 2010 Feb; 23(2):147-54. PubMed ID: 19744223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
    Nankivell BJ; PʼNg CH; OʼConnell PJ; Chapman JR
    Transplantation; 2016 Aug; 100(8):1723-31. PubMed ID: 27306529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.